NOVN - ノバン (Novan Inc.) ノバン

 NOVNのチャート


 NOVNの企業情報

symbol NOVN
会社名 Novan Inc (ノバン)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 ノーバン(Novan Inc)は後期段階の医薬品会社である。同社は一酸化窒素プラットフォームを使用することによって治療法の開発・商業化に従事する。同社は調整可能な新規化学物質(NCEs)の操作を可能とするNitricil技術によって候補製品を開発する。同社の製剤サイエンスは非活性成分を使用することによって皮膚に応用される時に一酸化窒素の放出のさらなる調整を可能とする。同社は第3相尋常性座瘡の治療用SB204、第2相外生殖器・肛門疣贅の治療用製品候補SB206、皮膚・爪の真菌感染の治療用試験中局所的な抗真菌剤SB208を開発している。同社は炎症性皮膚疾患の治療用SB204を開発している。同社のパイプラインはまた局所的クリーム製品候補SB414を含む。   ノバンは米国の医薬品企業。主に臨床段階で、皮膚科の疾患に対する治療薬の開発・商業化に従事する。皮膚の免疫反応で不可欠な一酸化窒素を用いて治療するプラットフォ―ムを開発し、同社パイプラインには「SB206」、「SB208」、「SB414」などがある。本社はノ―スカロライナ州ダ―ラム。   
本社所在地 4105 Hopson Road Morrisville NC 27560 USA
代表者氏名 Robert A. Ingram ロバートA.イングラム
代表者役職名 Independent Chairman of the Board
電話番号 +1 919-485-8080
設立年月日 38718
市場名 NASDAQ National Market System
ipoyear 2016年
従業員数 59人
url www.novan.com
nasdaq_url https://www.nasdaq.com/symbol/novn
adr_tso
EBITDA EBITDA(百万ドル) -30.26500
終値(lastsale) 2.63
時価総額(marketcap) 68486362.46
時価総額 時価総額(百万ドル) 65.23131
売上高 売上高(百万ドル) 2.67800
企業価値(EV) 企業価値(EV)(百万ドル) 52.27231
当期純利益 当期純利益(百万ドル) -28.42800
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Novan Inc revenues increased 26% to $1.3M. Net loss decreased 40% to $12.8M. Revenues reflect License and collaboration revenue increase of 33% to $1.3M. Lower net loss reflects Change in fair value of warrant increase from $0K to $4.3M (income) General and administrative - Balancing decrease of 28% to $4.8M (expense) Research and Development - Balancing decrease of 10% to $11.8M (expense).

 NOVNのテクニカル分析


 NOVNのニュース

   Eli Lil­ly Aban­dons IL-23 Psoriasis Program, Instead Will Focus On Ulcerative Colitis, Crohn's Disease Indications  2021/04/27 18:34:25 Benzinga
Tucked in its Q1 earnings release, Eli Lilly And Co (NYSE: LLY ) has scrapped its plans to seek approval for mirikizumab in psoriasis . The company decided not to enter the market despite the anti-IL-23p19 antibody outperforming Novartis AG’s (NYSE: NVS ) Cosentyx in a Phase 3 trial last year . AbbVie Inc’s (NYSE: ABBV ) anti-IL-23 antibody Skyrizi and Johnson & Johnson’s (NYSE:
   Truffa Farmaci Lombardia, 5 ospedali San Donato patteggiano, a giudizio Bayer e Novartis  2021/04/27 12:36:25 Investing.com Italy
https://it.investing.com/news/stock-market-news/truffa-farmaci-lombardia-5-ospedali-san-donato-patteggiano-a-giudizio-bayer-e-novartis-1995409
   Novartis Q1 sales, profit miss analyst expectations amid COVID-19 impact  2021/04/27 06:30:27 Investing.com
https://www.investing.com/news/stock-market-news/novartis-q1-sales-profit-miss-analyst-expectations-amid-covid19-impact-2486018
   Outlook on the Digital Respiratory Devices Global Market to 2030 - Focus on Sensors, Smart Inhalers & Nebulizers, Application, Countries and Competitive Landscape  2021/04/19 17:45:00 Benzinga
DUBLIN , April 19, 2021 /PRNewswire/ -- The "Global Digital Respiratory Devices Market 2021-2030: Focus on Sensors, Smart Inhalers & Nebulizers, Application, 9 Countries' Data, and Competitive Landscape" report has been added to ResearchAndMarkets.com's offering. The Global Digital Respiratory Devices Market is projected to reach $405.1 million by 2030. The study highlights that the market is set to witness a CAGR of 27.31% between 2021 and 2030. This comprehensive study of the global digital respiratory devices market covers the following: Market numbers on product types More than 35 key products present in the market Market share analysis for the global digital respiratory devices Market and its indications Detailed global and regional market share analysis Besides these parameters, the study also encompasses the market growth drivers, opportunities, market restraining factors, competition mapping, end-user analysis, and COVID-19 impact on the market. The study indicates that increasing prevalence of respiratory diseases, increasing adoption of digital technology among individuals, and treatment satisfaction with inhaled therapy among individuals are fueling the growth of the market.
   Novartis Taps Artios In Discovery Pact To Enhance Radioligand Portfolio  2021/04/07 11:08:04 Benzinga
Novartis AG (NYSE: NVS ) has struck a deal with UK-based Artios Pharma to access DNA damage response (DDR) targets that can potentially enhance its radioligand therapies. Artios is set to get $20 million upfront and up to $1.3 billion in milestones in return for the targets. During the three-year collaboration, Artios and Novartis will … Full story available on Benzinga.com
   Ark Funds, Illumina Invest In SomaLogic SPAC Deal: What Investors Should Know  2021/03/29 15:16:06 Benzinga
A leader in the proteomics field is going public with a SPAC deal announced Monday. The SPAC Deal: SomaLogic announced a SPAC deal with CM Life Sciences II Inc (NASDAQ: CMIIU ), valuing the company at $1.2 billion. A $375 million PIPE on the SPAC merger includes investments from SoftBank Group Corp (OTC: SFTBY ), T. Rowe Price, Illumina, Inc. (NASDAQ: ILMN ), Novartis AG (NYSE: NVS ) and accounts advised by Ark Invest. Kevin Conroy, the CEO of EXACT Sciences Corporation (NASDAQ: EXAS ) will join the board of directors after the merger is complete. Current shareholders of CM Life Sciences II will own 14% of the company after the merger. PIPE investors will own 20% of the company after the merger. About SomaLogic: Using … Full story available on Benzinga.com
   Novartis corrects chairman's comments about kickbacks case  2021/03/24 15:30:28 Investing.com
https://www.investing.com/news/stock-market-news/novartis-corrects-chairmans-comments-about-kickbacks-case-2456087
   Novartis’ $2B cancer drug spurs ‘groundbreaking’ PhIII data for prostate cancer  2021/03/23 13:11:17 Endpoints News
Continuing a streak of upbeat announcements on its radioligand portfolio, Novartis says that their Phase III study of 177Lu-PSMA-617 hit both co-primary endpoints on overall survival and radiographic progression-free survival for prostate cancer patients — setting up a likely approval some analysts believe would be worth more than a billion
   Autoinjectors Market Is Expected To Exhibit 18.1% CAGR By 2027 | Novartis AG, SHL Medical, Eli Lilly and Company  2021/03/23 12:54:31 OpenPR
Rise in anaphylaxis cases and increases in R&D activities by key players in the market are anticipated to drive the market. Rapid growth has been observed in adoption of biosimilars over branded drugs, which provides low cost treatment options for
   Rizatriptan Benzoate Market Trends and Growth by 2021-2026 | Merck, Pfizer, Roche, GSK, Mylan, TEVA, Novartis  2021/03/23 11:51:30 OpenPR
The global Rizatriptan Benzoate market size is projected to grow in the historic period resulted from economic growth in emerging markets, the rise in awareness of the benefits and developed nations towards Rizatriptan Benzoate costs and increasing production and growing
   Novartis corrects chairman's comments about kickbacks case  2021/03/24 15:30:28 Investing.com
https://www.investing.com/news/stock-market-news/novartis-corrects-chairmans-comments-about-kickbacks-case-2456087
   Novartis’ $2B cancer drug spurs ‘groundbreaking’ PhIII data for prostate cancer  2021/03/23 13:11:17 Endpoints News
Continuing a streak of upbeat announcements on its radioligand portfolio, Novartis says that their Phase III study of 177Lu-PSMA-617 hit both co-primary endpoints on overall survival and radiographic progression-free survival for prostate cancer patients — setting up a likely approval some analysts believe would be worth more than a billion
   Autoinjectors Market Is Expected To Exhibit 18.1% CAGR By 2027 | Novartis AG, SHL Medical, Eli Lilly and Company  2021/03/23 12:54:31 OpenPR
Rise in anaphylaxis cases and increases in R&D activities by key players in the market are anticipated to drive the market. Rapid growth has been observed in adoption of biosimilars over branded drugs, which provides low cost treatment options for
   Rizatriptan Benzoate Market Trends and Growth by 2021-2026 | Merck, Pfizer, Roche, GSK, Mylan, TEVA, Novartis  2021/03/23 11:51:30 OpenPR
The global Rizatriptan Benzoate market size is projected to grow in the historic period resulted from economic growth in emerging markets, the rise in awareness of the benefits and developed nations towards Rizatriptan Benzoate costs and increasing production and growing
   Booming CAGR of 14.4%, Monoclonal Antibodies Market to Surpass US$ 368.8 Billion by 2027 | Pfizer Inc., Novartis AG, Bayer AG, Sanofi S.A., F. Hoffmann-La Roche AG, Eli Lilly and Co., Merck & Co., Inc., GlaxoSmithKline Plc  2021/03/23 11:16:11 OpenPR
A new market study on the 2020-2027 Monoclonal Antibody Therapeutics Market with 100+ market data Tables, Pie Chat, Graphs & Figures spread through Pages and easy to understand detailed analysis. At present, the market is developing its presence. The Research report presents

 関連キーワード  (医薬品 米国株 ノバン NOVN Novan Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)